Nitric oxide (NO) participates in the control of contractility and heart rate, limits cardiac
remodeling after an infarction and contributes to the protective effect of ischemic pre-and …

The characterization and cloning of constitutive and inducible nitric oxide (NO)-synthesizing
enzymes and the development of specific inhibitors of the L-arginine NO pathway have …

It is generally held that the role of a specific control element can only be understood within
its physiological environment. The reviewed studies make it clear that there is a potent …

Prior studies from this laboratory, using untreated castrated (CASTRATE) rats and
testosterone‐treated castrated (TES‐TO) rats, have shown that the magnitude of the …

It has been proposed that NO may function as an endogenous cardioprotectant. We have
investigated whether modulation of NO levels (detected in coronary effluent by …

Nitric oxide (NO) is a powerful vasodilator and an inhibitor of platelet aggregation in vitro.
While the ability of NO to modulate vascular tone in vivo has been proven, only a few studies …

Pharmacological inhibition of nitric oxide synthase causes sustained hypertension in many
animal species. Although this hypertension has been attributed to inhibition of endothelium …

nitrodopamine (6-ND) is released from rat isolated atria, where it acts as a potent positive
chronotropic agent. The release of 6-ND from rat isolated atria and ventricles is significantly …

Background Inducible nitric oxide synthase (iNOS) is activated in cardiac disorders. We
investigated the contribution of increased iNOS activity to the development of left ventricular …

Studies in anesthetized animals have advanced the theory that there is an important
neurogenic component to the hypertension caused by pharmacological inhibition of nitric …